After attending ASN Kidney Week, Bluestar Principal Jeff Fineberg sits down with Dr. Pietro Canetta to talk all things IgA nephropathy (IgAN). After Dr. Canetta provides a brief summary of his IgAN lecture at Kidney Week, Emerging Therapeutic Options in IgA Nephropathy, the two discuss the Filspari (sparsentan) data presented from both the PROTECT study, in IgAN, the DUPLEX study, in FSGS. From there, Dr. Canetta opines on the value of surrogate endpoints in predicting the three D's of CKD: death, dialysis, and doubling of serum creatinine (SCr). Dr. Canetta briefly discusses Novartis' press release announcing the positive Phase II data with atrasentan, another ETA RA, before the conversation shifts to other drug classes and therapeutic targets, including SGLT2 inhibitors, and B-cell activation (i.e., APRIL/BAFF). Finally, Jeff asks Dr. Canetta about whether the recent advancements in IgAN are generalizable to other glomerular diseases, and what might be the determinants of this.

Jump to specific topics in the conversation:

00:00 Recap + guest intro/bio + Kidney Week lecture summary
05:05 Filspari (sparsentan) trial results from PROTECT (IgAN) and DUPLEX (FSGS)
12:25 Value of surrogate endpoints in predicting three D's - death, dialysis, and doubling of SCr - in glomerular disease
19:55 Atrasentan press release
23:05 The "four-hit" hypothesis of IgAN pathogenesis and SGLT2i
26:10 B-cell activation (APRIL/BAFF) as a therapeutic approach in IgAN
31:55 Generalizability (and lack thereof) of therapeutic approaches to other glomerular diseases
37:25 Where to learn more

Helpful links:

PROTECT Study (Filspari/sparsentan in IgAN)

DUPLEX Study (Filspari/sparsentan in FSGS)

Novartis press release (atrasentan in IgAN)

ENVISION Study (sibeprenlimab in IgAN)

Columbia Glomerular Center

For more information about Bluestar BioAdvisors, please visit our website.

Ep. 2 - Making Sense of the Latest IgAN Trials (with Dr. Pietro Canetta)